Fig. 2: Adjusted 96-week changes in the primary outcome and key secondary outcomes. | npj Parkinson's Disease

Fig. 2: Adjusted 96-week changes in the primary outcome and key secondary outcomes.

From: Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease

Fig. 2

The changes in the adjusted average of DaT-SPECT SBR (a), MIBG H/M ratio delay (b), MDS-UPDRS III (c), MoCA-J (d), MDS-UPDRS I (e), BDI-II (f), PDQ-39 summary index (g), and plasma NfL levels (h) from the baseline to week 96 are plotted with 95% confidence interval. Mixed-effects models for repeated measures (MMRM) are used to determine the adjusted average and p-values visualized with **p < 0.01, *p < 0.05. DaT dopamine transporter, MIBG metaiodobenzylguanidine, MDS-UPDRS Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, MoCA-J the Japanese version of the Montreal Cognitive Assessment, BDI-II Beck Depression Inventory-Second Edition, PDQ-39 Parkinson’s Disease Questionnaire-39, NfL neurofilament light chain.

Back to article page